Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
about
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsGenomic diversity of colorectal cancer: Changing landscape and emerging targetsCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesMolecular Subtypes and Personalized Therapy in Metastatic Colorectal CancerMolecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative SettingSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyHepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancerBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesImpact of somatic mutations on patterns of metastasis in colorectal cancerMolecular profiling in the treatment of colorectal cancer: focus on regorafenibBRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Beyond RAS and BRAF: a target rich disease that is ripe for pickingSystematic review: brain metastases from colorectal cancer--Incidence and patient characteristicsSurgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation StatusClinical Application of Targeted Next Generation Sequencing for Colorectal CancersRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerImpaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocksRAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution.Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.A systems biology approach to the global analysis of transcription factors in colorectal cancer.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.Biology of colorectal cancer.Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerIncidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastasesKRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypesA mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancerPrimary tumor location as a prognostic factor in metastatic colorectal cancer.
P2860
Q26738665-95CA4EB1-7230-4EB5-A119-CF441ABFF36BQ26739052-02B95FED-35F8-469F-AD62-E4223D15268EQ26741009-EC261A9F-95F7-4AF6-B51C-B74CB87C5B86Q26747329-9F304F3D-3E62-4DAE-9146-F878B6000D2DQ26749002-AF6E2480-C0A1-4E05-96E2-A010FC3B5DFFQ26751035-FA8F90E1-CCD6-4471-98E6-9B6048DF5C32Q26772267-788F7D11-B503-464D-94A2-E5256335F335Q26772276-C708B86C-31D1-46DB-9A8E-ECB035467893Q26772279-C24F5863-96ED-4A10-887C-F9B6AB864DE8Q26778296-0F415B67-E170-4725-9B03-3ABD7E19B01EQ27852942-6F595C3E-686C-4469-A151-23C683CB8FA7Q27853121-A197D69E-D82B-4745-8D2F-36D3A36EF774Q27853216-22ECBD06-C157-4AFD-8F5B-BFF0F8D32074Q27853224-DA2D8A9A-93B5-4ED8-8536-4174116F349BQ28066095-D7E5ADF2-6999-4F5A-9496-26D94CD795E2Q28066158-DE16CA20-7466-4D8A-8C8C-5548170CD021Q28075777-BD26C44C-F9BA-43F8-B4C5-A74DD0AA649EQ28077199-B29F4279-2570-4A05-BD55-50250C333853Q28080176-5AC18E0C-FE08-4AF5-9E5E-CD0B39A75FC5Q30358990-31B73235-4ECB-48D8-BBDC-C83A9E8E4B26Q30967175-FE7BB15E-BADF-413C-A4A2-D79230A5665FQ33813216-0ABEE714-6AE1-4C18-88DA-C0615B1A9972Q34067781-73B4BA7B-C8EA-4E8B-90C0-0172F14DA53EQ34308855-0689846E-A36A-4A57-8823-4009E5ECF653Q34361370-C6EBAE93-1521-4AD7-87A9-1FDAA94CDB5FQ34362289-49BF98E2-D235-4C9A-A49E-167FBBE055B2Q34442771-294D8110-E84C-4664-A212-3FEFF677DBE3Q34669618-46D02B3C-AF02-46B6-BE84-1418B04FB358Q34703562-A445594B-7F7F-40E2-BA79-197D5B164E1BQ35012020-1AC7A9ED-999D-477A-B6B4-0E358609E2B5Q35098287-E90AFD5B-03A4-4A34-9F6F-64DBB90161FAQ35124790-FDF44FED-C2AE-4DD5-AAC0-8AD500DF6EEEQ35187723-35BC98D2-08FD-4D0A-A6CB-4A5AD0839668Q35677169-925018B3-C1F0-48C9-964A-7BAEA56A360CQ35685684-076866FB-30F3-4747-A8AE-54DA3EDED043Q35773077-DC070E03-6428-4E00-B1AC-FAAFB0B2FFB4Q35777233-BC59BE6E-7D10-4211-9AEA-CDD54C95BD44Q35870363-98667E9A-7FD6-406D-90E2-F4BC1D155946Q35911017-0E542FF3-A136-4AC9-9D19-1DF83A456BC0Q36047405-042A02CF-6F07-4671-911E-B46D5C0499F4
P2860
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@ast
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@en
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@nl
type
label
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@ast
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@en
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@nl
prefLabel
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@ast
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@en
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@nl
P2093
P2860
P50
P356
P1433
P1476
Impact of BRAF mutation and mi ...... n metastatic colorectal cancer
@en
P2093
Atin Agarwal
Christopher H Lieu
Dipen M Maru
Jeanne Tie
Zhi-Qin Jiang
P2860
P304
P356
10.1002/CNCR.26086
P407
P577
2011-03-31T00:00:00Z